Evaxion Posts Three-Year Data for Personalized Melanoma Vaccine EVX-01
Evaxion Biotech reports three-year follow-up data for EVX-01, its AI-designed personalized therapeutic vaccine for melanoma, extending durability evidence.
Topic
Neoantigen Vaccine
Topic
Neoantigen Vaccine
Evaxion Reports Three-Year Data for Melanoma Vaccine EVX-01
Evaxion reports three-year data for melanoma vaccine EVX-01, a personalized neoantigen candidate; the disclosure headline omits s…
Evaxion Brings Three-Year EVX-01 Melanoma Data to ESMO 2026
Evaxion will present three-year Phase 2 follow-up on its personalized neoantigen vaccine EVX-01 in advanced melanoma at ESMO 2026…
An mRNA Cancer Vaccine Gave One Melanoma Patient a Path Forward
A melanoma diagnosis led one patient to an investigational mRNA cancer vaccine, STAT reports — a story that signals where skin-ca…
Elsner Highlights Personalized mRNA Therapies for High-Risk Melanoma
Dr. Caroline Elsner discusses personalized mRNA-based therapies for high-risk melanoma in an Oncodaily feature, as the adjuvant v…
Melanoma Vaccine 'Breakthrough': Which Cancers Come Next?
Oncology's melanoma vaccine pivot has shifted attention from proof-of-concept to pipeline. The Washington Post's headline framing…
Personalized Melanoma Vaccine Cuts Recurrence Risk at Five Years
A personalized melanoma vaccine reduced the risk of cancer recurrence over five years, NBC News reports — one of the longest dura…